67th Annual Scientific Sessions of the American College of Cardiology 2018

The Word from ACC 2018: ODYSSEY Outcomes

Highlights from ACC.2018: Poster presentations

Real-life experience with PCSK9 inhibition in familial hypercholesterolaemia Familial hypercholesteraemia (FH, inherited high cholesterol) is one of the key groups for whom PCSK9 inhibition is indicated. This prospective registry provided data on 44 patients with genetically verified FH attending a specialist lipid clinic in Norway….

Will the PCSK9 inhibitor trials change guidelines and practice?

Statins are the indisputable backbone of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD), with add-on ezetimibe proven to provide further benefit in high-risk patients.1 Yet it is clear that even with optimally tolerated statin therapy, a high residual cardiovascular risk persists. In ODYSSEY…

VIDEO: Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?

Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?

VIDEO: Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?

Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?

Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?

Will ODYSSEY Outcomes change the management of ACS patients?

What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?

How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?

Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?

Prof John Chapman discusses safety data from the ODYSSEY Outcomes study

Prof Henry Ginsberg discusses the ODYSSEY Outcomes topline data

Prof Greg Schwartz Clinical implications of ODYSSEY Outcomes

Prof Greg Schwartz Key results of ODYSSEY Outcomes

Prof Greg Schwartz Rationale and design of ODYSSEY Outcomes

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome

Top-line results presented at the 67th Scientific Sessions of the American College of Cardiology, Orlando, Florida provide definitive evidence for targeting PCSK9 inhibition to patients at highest risk with persistently elevated LDL cholesterol levels despite intensive statin therapy. Although further data are needed, this is…